Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergh, F. T.
Right arrow Articles by Holsboer, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergh, F. T.
Right arrow Articles by Holsboer, F.
Neurology 1999;53:772
© 1999 American Academy of Neurology


Articles

Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS

F. Then Bergh, MD, T. Kümpfel, MD, C. Trenkwalder, MD, R. Rupprecht, MD and F. Holsboer, MD, PhD

From the Max Planck Institute of Psychiatry, Neurology, Muenchen, Germany.

Address correspondence and reprint requests to Dr. Florian Then Bergh, Neurologische Klinik, Klinikum Grosshadern, Marchioninistr. 15, D-81377 Muenchen, Germany.

OBJECTIVE: To investigate whether dysregulation of the hypothalamo–pituitary–adrenal (HPA) axis is related to clinical characteristics in MS.

METHODS: The authors performed the combined dexamethasone–corticotropin-releasing hormone test (Dex-CRH test) in 60 MS patients and 29 healthy control subjects. In addition, the short adrenocorticotropic hormone (ACTH) test was performed in 39 consecutive patients. All patients had active disease and none were treated with glucocorticoids, immunosuppressants, or immunomodulators.

RESULTS: The patients had an exaggerated rise in plasma cortisol concentrations in the Dex-CRH test (p < 0.05), indicating hyperactivity of the HPA system. The degree of hyperactivity was moderate in relapsing–remitting MS patients (n = 38; area under the time-course curve for cortisol [AUC-Cort] 226.2 ± 38.9 arbitrary units [AU], mean ± SEM), intermediate in secondary progressive MS patients (n = 16; AUC-Cort, 286.8 ± 60.2 AU), and marked in primary progressive MS patients (n = 6; AUC-Cort, 670.6 ± 148.6 AU). Differences were significant between the three patient groups (p < 0.005), and between control subjects (n = 29; AUC-Cort, 150.8 ± 34.1 AU) and each patient group. Indicators of HPA axis activation correlated with neurologic disability (Kurtzke’s Expanded Disability Status Scale), but not with the duration of the disease, number of previous relapses, previous corticosteroid treatments, or depressed mood (Hamilton Depression Scale). The ACTH test was normal in 31 of the 33 patients studied.

CONCLUSION: HPA axis hyperactivity in MS is related to the clinical type of disease, with a suggestion of increasing HPA axis dysregulation with disease progression.

Key words: MS—Hypothalamo-pituitary-adrenal axis—Dexamethasone-CRH test.




This article has been cited by other articles:


Home page
Neurorehabil Neural RepairHome page
D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx
Origin of Fatigue in Multiple Sclerosis: Review of the Literature
Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100.
[Abstract] [PDF]


Home page
Mult SclerHome page
C Heesen, D C Mohr, I Huitinga, F T. Bergh, J Gaab, C Otte, and S M Gold
Stress regulation in multiple sclerosis-current issues and concepts
Multiple Sclerosis, March 1, 2007; 13(2): 143 - 148.
[Abstract] [PDF]


Home page
Mult SclerHome page
L. Krupp
Editorial
Multiple Sclerosis, August 1, 2006; 12(4): 367 - 368.
[PDF]


Home page
Mult SclerHome page
J E Martinez-Rodriguez, E Munteis, and J Roquer
Periodic hyperthermia and abnormal circadian temperature rhythm in a patient with multiple sclerosis
Multiple Sclerosis, August 1, 2006; 12(4): 515 - 517.
[Abstract] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
C Heesen, L Nawrath, C Reich, N Bauer, K-H Schulz, and S M Gold
Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?
J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 34 - 39.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Benou, Y. Wang, J. Imitola, L. VanVlerken, C. Chandras, K. P. Karalis, and S. J. Khoury
Corticotropin-Releasing Hormone Contributes to the Peripheral Inflammatory Response in Experimental Autoimmune Encephalomyelitis
J. Immunol., May 1, 2005; 174(9): 5407 - 5413.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
C. Heesen, G. Koehler, R. Gross, W. Tessmer, K.-H. Schulz, and S. M Gold
Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue
Multiple Sclerosis, February 1, 2005; 11(1): 51 - 57.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. M. L. van Winsen, D. F. R. Muris, C. H. Polman, C. D. Dijkstra, T. K. van den Berg, and B. M. J. Uitdehaag
Sensitivity to Glucocorticoids Is Decreased in Relapsing Remitting Multiple Sclerosis
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 734 - 740.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
M. Gottschalk, T. Kumpfel, P. Flachenecker, M. Uhr, C. Trenkwalder, F. Holsboer, and F. Weber
Fatigue and Regulation of the Hypothalamo-Pituitary-Adrenal Axis in Multiple Sclerosis
Arch Neurol, February 1, 2005; 62(2): 277 - 280.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
I. HUITINGA, Z. A. ERKUT, D. VAN BEURDEN, and D. F. SWAAB
The Hypothalamo-Pituitary-Adrenal Axis in Multiple Sclerosis
Ann. N.Y. Acad. Sci., May 1, 2003; 992(1): 118 - 128.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
Z A Erkut, E Endert, I Huitinga, and D F Swaab
Cortisol is increased in postmortem cerebrospinal fluid of multiple sclerosis patients: relationship with cytokines and sepsis
Multiple Sclerosis, June 1, 2002; 8(3): 229 - 236.
[Abstract] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. T. Bergh, T. Kümpfel, A. Grasser, R. Rupprecht, F. Holsboer, and C. Trenkwalder
Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo-Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1610 - 1615.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.